OXIGENE INC. (OXGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: schzammm who wrote (255)	9/12/2003 8:47:21 PM
From: Nikole Wollerstein	Read Replies (2) of 273

"OXiGENE started with a Mkt Outperform rating at Rodman & Renshaw; target $17 (OXGN) 11.54 -0.23: Rodman & Renshaw initiates coverage with a Mkt Outperform rating and $17 target; firm expects significant news flow from the co over the next 12 months, including the signing of a partnership agreement with a pharma or large biotech co by the end of 2003, as well as clinical development news for other compounds in the pipeline, notably Oxi-4503 and Oxi-6197." What an idiotic recomendationes: if CAP4 work OXGN goes too 100 if not too 2

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next